Summary: Retatrutide is dosed in milligrams (mg) per weekly subcutaneous injection not in units and remains an investigational medicine with no MHRA or EMA approval as of mid-2025
"Novel Peptide Therapeutics for Weight Management and Metabolic Disease." The Lancet Diabetes & Endocrinology, 11(2), 123-138
GLP-1 RAs are currently being investigated for various new areas, such as cardiovascular diseases, non-alcoholic steatohepatitis (NASH), Alzheimers disease, and chronic kidney disease
Frequently, pigmentation is also found on the tongue, gingiva, and palatal mucosa
At Aire Peptides, each batch is produced using advanced synthesis methods and undergoes both internal verification and independent third-party testing to ensure consistency, identity, and purity